|
LUC7L2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.27675647831893E-14 |
| Normal-vs-Stage2 |
1.68599999961216E-07 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
6.74404976308551E-12 |
| Stage1-vs-Stage2 |
6.096400E-01 |
| Stage1-vs-Stage3 |
7.977400E-03 |
| Stage1-vs-Stage4 |
2.054000E-01 |
| Stage2-vs-Stage3 |
2.704400E-02 |
| Stage2-vs-Stage4 |
1.667030E-01 |
| Stage3-vs-Stage4 |
4.683000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.87943999999662E-05 |
| Normal-vs-Asian |
2.21609997019812E-09 |
| Caucasian-vs-AfricanAmerican |
3.982400E-01 |
| Caucasian-vs-Asian |
2.047000E-01 |
| AfricanAmerican-vs-Asian |
9.515400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.25455201782643E-14 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
6.788200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.67155178587564E-12 |
| Normal-vs-Age(41-60Yrs) |
7.96029908656237E-14 |
| Normal-vs-Age(61-80Yrs) |
1.65067959301268E-12 |
| Normal-vs-Age(81-100Yrs) |
4.17310000000448E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.704000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.019200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.544970E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.840600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.386800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.559600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.22750000003591E-06 |
| Classical-VS-Follicular |
4.141000E-01 |
| Classical-VS-Other |
9.947400E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
2.33069999999724E-05 |
| Tall-VS-Other |
2.826200E-02 |
| Tall-VS-Normal |
1.11022302462516E-16 |
| Follicular-VS-Other |
8.022600E-01 |
| Follicular-VS-Normal |
1.01949999997686E-07 |
| Other-VS-Normal |
3.836900E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.77475828372553E-14 |
| Normal-vs-N1 |
5.79210013285092E-11 |
| N0-vs-N1 |
3.134600E-01 |
|
|
